Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2025-12-25 @ 12:38 AM
NCT ID:
NCT01382667
Eligibility Criteria:
Inclusion Criteria:
* Patients with newly diagnosed cancer (lung and breast cancer),
* Patients currently free of active disease
Exclusion Criteria:
* History of cerebral edema, primary and secondary brain neoplasm with signs and symptoms of raised intracranial pressure and/or brain metastases,
* Signs of marked hepatic or renal dysfunction, cardiac failure
* Signs of dyspepsia, peptic ulcer, gastric surgery or prior diagnosis of other cancer
* Administration of drugs interfering with GI motility (i.e. antisecretory, prokinetic, or antibiotic drugs) as well as the exposition to radiotherapy, four weeks prior to the examination
* Referred episode of nausea of any severity within 24 h prior to antiemetic therapy, if they had experienced vomiting in the previous 24 h,
* Pregnancy or lactating
* Concomitant administration of agents known to have significant antiemetic activity, including benzodiazepines and other corticosteroids
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT01382667
Study Brief:
Protocol Section:
NCT01382667